Slide 1: Adherium FY17 Full Year Results
Adherium FY17 Full Year Results Investor Update August 2017
Slide 2: Vision
Vision Adherium will maximize our enterprise value by becoming the adherence company in Digital Health through employing device data to ensure proper patient use of medication, resulting in: • reducing costs of healthcare, • enhancing comprehensive care, • and improving the quality of patients’ live
Slide 3: Company Development
Company Development OEM Pharma Accelerated Growth Product Development Distribution Agreement - Commercialization Platform Development Signed AstraZeneca Support AstraZeneca global Company Formation Accelerated Growth Distribution Agreement expansion 1st Commercial Intellectual Property Agreement Dev
Slide 4: Fast Facts About Adherium
Fast Facts About Adherium Technical Commercial Strategic and Clinical ✓ 15 years of experience in developing ✓ Partnership with AZ moving into ✓ Route to sustainable revenues and manufacturing Smartinhalers commercial activity with launch in across multiple channels ✓ In depth knowledge of medical o
Slide 5: Key Drivers to Shareholder Value
Key Drivers to Shareholder Value Adherium is at the center of the rapidly growing digital health sector ✓ $290B of avoidable US healthcare costs, $34B in respiratory diseases alone resulting from non-adherence being addressed by Adherium’s solution ✓ Commercial stage digital health company with the
Slide 6: FY18 Guidance and Assumptions
FY18 Guidance and Assumptions ✓ AZ • Ship a minimum of 25,000 devices • Obtain FDA 501(k) clearance to market SmartTouch for Symbicort pMDI in the USA • Expand Adherium’s offering beyond AZ’s Symbicort medication ✓ Launch medication adherence service solution • NZ: Go live Q1, obtain 1,300 active us
Slide 7: IP Assets
IP Assets ✓ Adherium IP rights cover the Smartinhaler™ proprietary digital adherence monitoring platform; ✓ Registered and unregistered rights protecting Smartinhaler™ hardware and software; ✓ Adherium patent portfolio is relevant to compliance monitors for use with most market-leading inhalers: pMD
Slide 8: Market Opportunities for Asthma and COPD
Market Opportunities for Asthma and COPD Healthcare Economic Burden of Asthma Adherium’s Clinically Proven Outcomes Patients Economic Burden More patients achieving 80% 3.4x adherence to preventative medication1 Worldwide 334M US$ 100B+ 5x Reduction in asthma-related hospitalization1 U.S. 25M US$ 56
Slide 9: Sale Strategies
Sale Strategies Aggressive commercialization strategy focuses on building from the OEM channel, leveraging Direct to Consumer channel to grow active user number, creating a market pull to Payer while developing undeniable healthcare economic data. The FY18 sales strategy priorities are listed below
Slide 10: AstraZeneca Partnership
AstraZeneca Partnership OEM DTC P4P Pharma partnerships… … leading to partnership User Commercial roll-out Acquisition bringing users to the platform ✓ First commercial agreement in the market More users more data ✓ Over 100,000 devices sold To support Pay for Performance ✓ Multiple market and pro
Slide 11: Results Review
adherium% Results Review
Slide 12: Executive Summary – Investing for growth
Executive Summary – Investing for growth 12 months to 15 months to Change % on comparable June 30, 2017 June 30, 2016 period basis Revenue $2.3m $2.6m 12% increase Gross profit $1.2m $1.3m 13% increase 49% margin 49% margin Other income (grants and interest) $1.0m $0.9m 50% increase Operating expens
Slide 13: Operational Review
Operational Review ✓ Delivered 18,000 connected devices in the year, compared with 30,000 in the 15 months to June 2016 (prior year included initial market launch volume from AZ). Total devices sold now exceed 100,000. ✓ Sales highlights related to: • AstraZeneca’s deployments of Adherium’s SmartTur
Slide 14: Cost Analysis
Cost Analysis ✓ Cost of goods were consistent with gross margin at 49% in FY16 and FY17 ✓ Operating expenses included non-cash expenses of $748,000 related to depreciation and amortizations, and employee share plan expense (FY16: $1m including non-cash interest and product development costs) ✓ Salar
Slide 15: Execution
adherium% Execution
Slide 16: Execution Priorities
Execution Priorities ✓ Maintain focus on the AstraZeneca business, enabling continuation of rollout globally. ✓ Build HQ and commercial team in Silicon Valley (CEO, CFO, VP of Marketing by end of 2017). ✓ Direct-to-Consumer business • New Zealand – 1,300 active users by June 2018 • Launch in USA – i
Slide 17: Summary
Summary Work with AstraZeneca has evolved from development to commercial. Adherium’s focus is commercial – getting our technology in the hands of the maximum number of active users. We’ve launched our Direct-to-Consumer offering in New Zealand. We are committed to demonstrate our ability to get our
Slide 18: Forward Looking Statement
Forward Looking Statement The following material is of a general nature and has only been prepared as a presentation aid. This presentation does NOT contain all of the information that may be required for evaluating Adherium Limited ACN 605 352 510 (Adherium® ), its assets, prospects or potential op
Slide 19: Thank You
Thank You Adherium Ltd © 2017 19